Annie A Wu1, Elizabeth Jaffee1, Valerie Lee2. 1. Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 488, Baltimore, MD, 21287, USA. 2. Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 488, Baltimore, MD, 21287, USA. Vlee32@jhmi.edu.
Abstract
PURPOSE OF REVIEW: Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed. RECENT FINDINGS: We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials. As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.
PURPOSE OF REVIEW: Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed. RECENT FINDINGS: We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials. As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.
Entities:
Keywords:
Cancer vaccines; Immunotherapy; Pancreatic adenocarcinoma
Authors: Agnes Witkiewicz; Timothy K Williams; Joseph Cozzitorto; Brandice Durkan; Shayna L Showalter; Charles J Yeo; Jonathan R Brody Journal: J Am Coll Surg Date: 2008-03-04 Impact factor: 6.113
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru Journal: J Immunother Date: 2013-09 Impact factor: 4.456
Authors: KiBem Kim; Andrew D Skora; Zhaobo Li; Qiang Liu; Ada J Tam; Richard L Blosser; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou Journal: Proc Natl Acad Sci U S A Date: 2014-07-28 Impact factor: 11.205
Authors: Erik S Knudsen; Vishnu Kumarasamy; Sejin Chung; Amanda Ruiz; Paris Vail; Stephanie Tzetzo; Jin Wu; Ram Nambiar; Jared Sivinski; Shailender S Chauhan; Mukund Seshadri; Scott I Abrams; Jianmin Wang; Agnieszka K Witkiewicz Journal: Gut Date: 2020-05-18 Impact factor: 23.059
Authors: Matthew R Farren; Layal Sayegh; Michael Brandon Ware; Hsiao-Rong Chen; Jingjing Gong; Yan Liang; Alyssa Krasinskas; Shishir K Maithel; Mohammad Zaidi; Juan M Sarmiento; David Kooby; Pretesh Patel; Bassel El-Rayes; Walid Shaib; Gregory B Lesinski Journal: JCI Insight Date: 2020-01-16